College of Medicine / About / Departments / Biomedical Science Department / Matthew Robson, Ph.D.


Research Assistant Professor of Biomedical Science

Tel. (561)799-8100


Matthew James Robson, Ph.D. is currently a Research Assistant Professor within the Brain Institute of the Charles E. Schmidt College of Medicine at Florida Atlantic University (FAU). Dr. Robson completed his Ph.D. in Pharmaceutical and Pharmacological Sciences at West Virginia University in 2013. He was a postdoctoral fellow in the Department of Pharmacology at Vanderbilt University School of Medicine prior to his arrival to FAU in 2016. Dr. Robson’s primary research interest is the development of novel therapeutics that are effective treatments for neuropsychiatric disorders such as autism spectrum disorder and depression.

  • 2007: Bachelor of Science, Biochemistry, Canisius College, Buffalo, NY
  • 2013: Ph.D., Pharmaceutical and Pharmacological Science, West Virginia University, Morgantown, WV

  • 2016 – Present: Postdoctoral Fellow, Brain Institute, Charles E. Schmidt College of Medicine, Florida Atlantic University, Jupiter, FL
  • 2013-2016: Postdoctoral Fellow, Department of Pharmacology, School of Medicine, Vanderbilt University, Nashville, TN
  • 2008-2013: Graduate Research Assistant, Department of Pharmaceutical Science, School of Pharmacy, West Virginia University, Morgantown, WV
  • 2004-2008: Research Assistant, DENT Neurologic Institute, Buffalo, NY

  • Robson MJ, Zhu CB, Quinlan MA, Botschner DA, Baganz NL, Lindler KM, Thome JG, Hewlett WA, Blakely RD. Generation and characterization of mice expressing a conditional allele of the interleukin-1 receptor type 1. PLOS One. 2016. DOI: 10.1371/journal.pone.0150068. PubMed ID: 26930558
  • Lucke-Wold BP, Turner RC, Logsdon AF, Nguyen L, Bailes JE, Lee JM, Robson MJ, Omalu BI, Huber JD, Rosen CL. Endoplasmic reticulum stress implicated in chronic traumatic encephalopathy. Journal of Neurosurgery. 2016. 124(3): 687-702. PubMed ID: 26381255
  • Baganz NL, Lindler KM, Zhu CB, Smith JT, Robson MJ, Iwamoto H, Deneris ES, Hewlett WA, Blakely RD. A requirement of serotonergic p38α mitogen activated protein kinase for peripheral immune system activation of serotonin uptake and serotonin linked behaviors. Translational Psychiatry. 2015. 5(e671). PubMed ID: 26529424
  • Nguyen L, Robson MJ, Healy JR, Scandinaro AL, Matsumoto RR. Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. PLOS One. 2014. 9(2): e89985. PubMedID: 24587167
  • Robson MJ, Turner RC, Naser ZJ, Huber JD, McCurdy CR, Matsumoto RR. SN79, a sigma receptor ligand, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation. Experimental Neurology. 2014. 254: 180-189. PubMed ID: 24508558
  • Robson MJ, Turner RC, Naser ZJ, McCurdy CR, Huber JD, Matsumoto RR. SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation and cytokine upregulation. Experimental Neurology. 2013. 247: 134-142. PubMed ID: 23631864
  • Robson MJ, Seminerio MJ, McCurdy CR, Coop A, Matsumoto RR. Sigma receptor antagonist attenuation of methamphetamine-induced neurotoxicity is correlated to body temperature modulation. Pharmacological Reports. 2013. 65(2): 343-349. PubMed ID: 23744418
  • Turner RC, Lucke-Wold B, Robson MJ, Omalu BI, Petraglia AL, Bales JE. Repetitive traumatic brain injury and development of chronic traumatic encephalopathy: a potential role for biomarkers in diagnosis, prognosis and treatment? Frontiers in Neurology. 2013. 3: 186. PubMed ID: 23335911
  • Robson MJ, Noorbakhsh B, Seminerio MJ, Matsumoto RR. Sigma-1 receptors: potential targets for the treatment of substance abuse. Current Pharmaceutical Design. 2012. 18: 902-919. PubMed ID: 22288407
  • Robson MJ, Elliott M, Seminerio MJ, Matsumoto RR. Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo. European Neuropsychopharmacology. 2012. 22(4): 308-317. PubMed ID: 21911285

View Pubmed Feed ⇉

Scholarly Activity

Past Support

  • Training Program in Ion Channel and Transporter Biology – T32 Institutional Training Grant NS007491 – Vanderbilt University (PI Knollman)
  • p38α MAPK Signaling: Novel Therapeutic Target for the Treatment of Autism Spectrum Disorder – PhRMA Foundation Pharmacology/Toxicology Postdoctoral Fellowship (PI Robson)

Honors and awards

  • 2016: NIDA Travel Award – International Society for Serotonin Research Meeting – Seattle, WA
  • 2016: ASPET Neuropharmacology Division Postdoctoral Best Presentation Award
  • 2016: ASPET Neuropharmacology Division Postdoctoral Travel Award
  • 2014: Vanderbilt ASPIRE Federal STEM Policy Externship
  • 2014: ASPET James A. Bain Travel Award - 17th World Congress of Basic and Clinical Pharmacology – Cape Town, South Africa
  • 2014: Early Career Science Policy Fellowship – Society for Neuroscience
  • 2012: ASPET Washington Fellows Fellowship Recipient
  • 2010: Student/Trainee Award – American College of Clinical Pharmacology

Last Modified 6/21/22